nach oben

Journal of Neuro-Oncology

Erschienen in:

29.05.2017 | Laboratory Investigation

Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells

verfasst von: Ryogo Kikuchi, Oltea Sampetrean, Hideyuki Saya, Kazunari Yoshida, Masahiro Toda

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

DEP domain containing 1 (DEPDC1) is a novel oncoantigen expressed in cancer cells, which presents oncogenic activity and high immunogenicity. Although DEPDC1 has been predicted to be a useful antigen for the development of a cancer vaccine, its pathophysiological roles in glioma have not been investigated. Here, we analyzed the expression and function of DEPDC1 in malignant glioma. DEPDC1 expression in glioma cell lines, glioma tissues, and brain tumor initiating cells (BTICs) was assessed by western blot and quantitative polymerase chain reaction (PCR). The effect of DEPDC1 downregulation on cell growth and nuclear factor kappa B (NFκB) signaling in glioma cells was investigated. Overall survival was assessed in mouse glioma models using human glioma cells and induced mouse brain tumor stem cells (imBTSCs) to determine the effect of DEPDC1 suppression in vivo. DEPDC1 expression was increased in glioma cell lines, tissues, and BTICs. Suppression of endogenous DEPDC1 expression by small interfering RNA (siRNA) inhibited glioma cell viability and induced apoptosis through NFκB signaling. In mouse glioma models using human glioma cells and imBTSCs, downregulation of DEPDC1 expression prolonged overall survival. These results suggest that DEPDC1 represents a target molecule for the treatment of glioma.

Nur mit Berechtigung zugänglich

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330 CrossRefPubMed

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. doi:10.1056/NEJMoa1308573 CrossRefPubMedPubMedCentral

Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. doi:10.1056/NEJMoa1308345 CrossRefPubMed

Stupp R, Wong ET, Kanner AA et al (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48(14):2192–2202. doi:10.1016/j.ejca.2012.04.011 CrossRefPubMed

Lee J, Kotliarova S, Kotliarov Y et al (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9(5):391–403. doi:10.1016/j.ccr.2006.03.030 CrossRefPubMed

Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. doi:10.1038/nature03031.1.CrossRefPubMed

Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828. doi:10.1038/nature03128 PubMed

Fukaya R, Ohta S, Yamaguchi M et al (2010) Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1. Cancer Lett 291(2):150–157. doi:10.1016/j.canlet.2009.10.010 CrossRefPubMed

Zhu Z, Khan MA, Weiler M et al (2014) Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell 15(2):185–198. doi:10.1016/j.stem.2014.04.007 CrossRefPubMed

10.

Fukaya R, Ohta S, Yaguchi T et al (2016) MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53. Cancer Res. doi:10.1158/0008-5472.CAN-15-1011 PubMed

11.

Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M (2004) Identification of a human glioma antigen, SOX6, recognized by patients’ sera. Oncogene 23:1420–1427. doi:10.1038/sj.onc.1207252 CrossRefPubMed

12.

Ueda R, Ohkusu-Tsukada K, Fusaki N et al (2010) Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer 126(4):919–929. doi:10.1002/ijc.24851 PubMed

13.

Takahashi S, Fusaki N, Ohta S et al (2012) Downregulation of KIF23 suppresses glioma proliferation. J Neurooncol 106(3):519–529. doi:10.1007/s11060-011-0706-2 CrossRefPubMed

14.

Saito K, Iizuka Y, Ohta S et al (2014) Functional analysis of a novel glioma antigen, EFTUD1. Neuro Oncol 16(12):1618–1629. doi:10.1093/neuonc/nou132 CrossRefPubMedPubMedCentral

15.

Lollini P, Cavallo F, Nanni P, Forni G (2006) Vaccines for tumour prevention. Nat Rev Cancer 6(3):204–216. doi:10.1038/nrc1815 CrossRefPubMed

16.

Kanehira M, Harada Y, Takata R et al (2007) Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 26(44):6448–6455. doi:10.1038/sj.onc.1210466 CrossRefPubMed

17.

Obara W, Ohsawa R, Kanehira M et al (2012) Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol 42(7):591–600. doi:10.1093/jjco/hys069 CrossRefPubMed

18.

Kassambara A, Schoenhals M, Moreaux J et al (2013) Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS ONE 8(4):e62752. doi:10.1371/journal.pone.0062752 CrossRefPubMedPubMedCentral

19.

Miyata Y, Kumagai K, Nagaoka T et al (2015) Clinicopathological significance and prognostic value of Wilms’ tumor gene expression in colorectal cancer. Cancer Biomark 15:789–797. doi:10.3233/CBM-150521 CrossRefPubMed

20.

Yuan S-G, Liao W-J, Yang J-J, Huang G-J, Huang Z-Q (2014) DEP domain containing 1 is a novel diagnostic marker and prognostic predictor for hepatocellular carcinoma. Asian Pac J Cancer Prev 15(24):10917–10922. http://www.ncbi.nlm.nih.gov/pubmed/25605201

21.

Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Langmoen IA (2015) Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. Oncotarget. doi:10.18632/oncotarget.4613.PubMedPubMedCentral

22.

Sampetrean O, Saga I, Nakanishi M et al (2011) Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia 13(9):784–791. doi:10.1593/neo.11624 CrossRefPubMedPubMedCentral

23.

Osuka S, Sampetrean O, Shimizu T et al (2013) IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells 31(4):627–640. doi:10.1002/stem.1328 CrossRefPubMed

24.

Harada Y, Kanehira M, Fujisawa Y et al (2010) Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res 70:5829–5839. doi:10.1158/0008-5472.CAN-10-0255 CrossRefPubMed

25.

Sendoel A, Maida S, Zheng X et al (2014) DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nat Cell Biol 16(8):812–820. doi:10.1038/ncb3010 CrossRefPubMed

26.

Denning DP, Hirose T (2014) Anti-tubulins DEPendably induce apoptosis. Nat Cell Biol 16(8):741–743. doi:10.1038/ncb3012 CrossRefPubMed

27.

Ishikawa H, Imano M, Shiraishi O, Yasuda A (2013) Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer. Gastric Cancer. doi:10.1007/s10120-013-0258-6 PubMed

28.

Suzuki H, Fukuhara M, Yamaura T et al (2013) Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med 11:97. doi:10.1186/1479-5876-11-97 CrossRefPubMedPubMedCentral

29.

Kono K, Mizukami Y, Daigo Y et al (2009) Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 100(8):1502–1509. doi:10.1111/j.1349-7006.2009.01200.x CrossRefPubMed

30.

Izumoto S, Tsuboi A, Oka Y et al (2008) Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963–971. doi:10.3171/JNS/2008/108/5/0963.CrossRefPubMed

31.

Mi Y, Zhang C, Bu Y et al (2015) DEPDC1 is a novel cell cycle related gene that regulates mitotic progression. BMB Rep 48(7):413–418CrossRefPubMedPubMedCentral

Titel: Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells
verfasst von: Ryogo Kikuchi
Oltea Sampetrean
Hideyuki Saya
Kazunari Yoshida
Masahiro Toda
Publikationsdatum: 29.05.2017
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2457-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy

Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience

Key rates for the grades and transformation ability of glioma: model simulations and clinical cases

SPECT imaging and radionuclide therapy of glioma using 131I labeled Buthus martensii Karsch chlorotoxin

Impact of treatment on survival of patients with secondary glioblastoma

A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie